While the Buy rating suggests continued confidence in Adverum Biotechnologies' long-term prospects, the significant reduction in the price target could indicate concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for ADVM's stock, but the maintained Buy rating could buffer negative impacts.